|Rexahn Pharmaceuticals, Inc.|
15245 Shady Grove Road
United States - Map
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.
|Dr. Peter D. Suzdak Ph.D.,
Chief Exec. Officer and Director
|Dr. Chang H. Ahn Ph.D.,
Founder, Chairman Emeritus and Chief Scientist
|Dr. Tae Heum Jeong D. Mgt.,
Chief Financial Officer, Sr. VP and Sec.
|Dr. Ely Benaim M.D.,
Chief Medical Officer
|Dr. Madhukar H. Trivedi M.D.,
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|